gms | German Medical Science

G-I-N Conference 2012

Guidelines International Network

22.08 - 25.08.2012, Berlin

Financing of Clinical Practice Guidelines (CPG) – what do we really know?

Meeting Abstract

  • J. Köpp - Agency for Quality in Medicine, Berlin, Germany
  • D. Rütters - Agency for Quality in Medicine, Berlin, Germany
  • T. Langer - Agency for Quality in Medicine, Berlin, Germany
  • B. Weikert - Agency for Quality in Medicine, Berlin, Germany
  • J. Schirm - Agency for Quality in Medicine, Berlin, Germany
  • L. Fishman - Agency for Quality in Medicine, Berlin, Germany
  • M. Nothacker - Agency for Quality in Medicine, Berlin, Germany
  • G. Ollenschläger - Agency for Quality in Medicine, Berlin, Germany
  • S. Weinbrenner - Agency for Quality in Medicine, Berlin, Germany

Guidelines International Network. G-I-N Conference 2012. Berlin, 22.-25.08.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocP055

DOI: 10.3205/12gin167, URN: urn:nbn:de:0183-12gin1670

Published: July 10, 2012

© 2012 Köpp et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: Guideline financing is an important issue as CPG development is resource consuming, funding often is inadequate and financial conflicts of interest can arise constituting a risk of biased recommendations.

Objectives: The aim of this work was to investigate which kind of costs are associated in connection with guideline development, who are the most common guideline financiers worldwide and how much CPG development costs.

Methods: A literature search in PubMed was performed. We used the keywords `finance`, `pay` or `funding` combined with the keyword `guideline`. Our search strategy resulted in a total of 118 articles. Additionally, we analysed home pages of guideline organisations and their guideline manuals. Furthermore, we analysed our own costs for guideline development. Currently we are preparing an international survey of guideline financing.

Results: The lion´s shares of costs are labour costs. The literature search in Medline showed insufficient information regarding guideline financing. Some guideline organisations give no information regarding their financing neither on their home page nor in the manuals. Most guideline developers are at least partially funded by their national government. Costs are differing substantially, for example ca. 130.000 £ per guideline in Netherlands and ca. 1 Mill. £ for a SIGN guideline. Additionally, we will present our results from the survey.

Discussion: Costs and financing of CPG show a wide variety. Despite the major relevance of guideline financing, only insufficient information is published.

Implications for guideline developers/users: Disclosure and discussion of guideline financing is paramount to ensure quality and credibility of CPG.